Top-News
Gesundheitswesen: Ausstattung u. Produkte USA

Seelos Therapeutics Inc News

Aktie
WKN:  A40DKU ISIN:  US81577F3073 US-Symbol:  SEEL
0,5723 €
+0,00 €
0,00%
0,6198 $ 24.06.24
Handeln Depot/Watchlist
Aktienanzahl *
622,92 Tsd.
Marktkapitalisierung *
323,82 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 16.05.2024

Unternehmensmeldungen

03.05.18 - GlobeNewswire
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results: Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May ...
16.04.18 - GlobeNewswire
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
Apricus Biosciences Announces Outcome of Vitaros(TM) End-​of-Review Meeting with FDA FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros ...
28.03.18 - GlobeNewswire
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a ...
27.03.18 - GlobeNewswire
Apricus Biosciences Announces Proposed Public Offering
Apricus Biosciences Announces Proposed Public Offering SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...
26.03.18 - GlobeNewswire
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-​of-Review Meeting with FDA Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) ...
01.03.18 - GlobeNewswire
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Company Expects to Submit Vitaros End of Review ...
21.02.18 - GlobeNewswire
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- ...
16.02.18 - GlobeNewswire
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM) Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 ...
26.10.17 - GlobeNewswire
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus ...
10.10.17 - GlobeNewswire
Apricus Biosciences to Present at the 2017 BIO Investor Forum
Apricus Biosciences to Present at the 2017 BIO Investor Forum SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...
11.09.17 - GlobeNewswire
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-​The-Market SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), ...
05.09.17 - GlobeNewswire
Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...
31.08.17 - GlobeNewswire
Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission
Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE ...
29.08.17 - GlobeNewswire
Apricus Biosciences Files NDA Resubmission for Vitaros(TM)
Apricus Biosciences Files NDA Resubmission for Vitaros(TM) Approval Decision Expected in First Quarter 2018 SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus ...
02.08.17 - GlobeNewswire
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results Vitaros Drug-​Device Human Factor Studies Successfully Completed Vitaros U.S. NDA ...
26.07.17 - GlobeNewswire
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus ...
04.05.17 - GlobeNewswire
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
Apricus Biosciences Announces the Initiation of Vitaros Drug-​Device Human Factors Study Vitaros U.S. NDA Re-​Submission on Track for Third Quarter 2017 SAN DIEGO, May 04, ...
04.05.17 - GlobeNewswire
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus ...
02.05.17 - GlobeNewswire
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ...
21.04.17 - GlobeNewswire
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering SAN DIEGO, April 21, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a ...

Newssuche

Videos

newspaper
03.07.24
Technical Trading: Bund Future Long Chance
Bund Future Long Typ: Turbo Open End WKN: VM3CG4 Hebel: 7,32 Laufzeit: OpenEnd Einstieg: Market ... Mehr »